Portola Pharmaceuticals to Present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference

Portola Pharmaceuticals to Present at the Wells Fargo Securities Research and 
Economics 2013 Healthcare Conference 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/12/13 --  Portola
Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that William
Lis, chief executive officer, will present at the Wells Fargo
Securities Research and Economics 2013 Healthcare Conference on
Tuesday, June 18, 2013, at 3:30 p.m. Eastern Time in Boston. The
presentation will be webcast live and available for replay from
Portola's website at www.portola.com in the Investor Relations
About Portola Pharmaceuticals, Inc. 
 Portola is a biopharmaceutical
company focused on the development and commercialization of novel
therapeutics in the areas of thrombosis (blood clots), other
hematologic disorders and inflammation for patients who currently
have limited or no approved treatment options. Portola's current
development-stage portfolio consists of three compounds discovered
through its internal research efforts and one discovered by Portola
scientists during their time at a prior company. Portola's two lead
programs address significant unmet medical needs in the area of
Portola's lead compound, betrixaban, is an investigational, novel,
oral, once-daily inhibitor of Factor Xa in Phase 3 development for
extended duration prophylaxis (preventive treatment) of a form of
thrombosis known as venous thromboembolism (VTE) in acute medically
ill patients. Currently, there is no anticoagulant approved for
extended duration VTE prophylaxis in this population.  
Portola's second lead development candidate, PRT4445, which has a
tentatively approved International Nonproprietary Name (INN) of
andexanet alfa, is a recombinant protein designed to reverse the
anticoagulant activity in patients treated with a Factor Xa inhibitor
who suffer an uncontrolled bleeding episode or undergo emergency
surgery. Portola has entered into collaboration agreements with
Bristol-Myers Squibb Company and Pfizer Inc. and with Bayer Pharma AG
and Janssen Pharmaceuticals, Inc. to study andexanet alfa with
Eliquis(R) (apixaban) and XARELTO(R) (rivaroxaban), respectively, in
Portola's Phase 2 studies. Portola retains full, worldwide commercial
rights with respect to andexanet alfa.  
Portola's third product candida
te, PRT2070, is an orally available
kinase inhibitor being developed for hematologic (blood) cancers and
inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk)
and janus kinases (JAK), enzymes that regulate important signaling
pathways. Subject to regulatory approval, Portola plans to initiate a
Phase 1/2 clinical study of PRT2070 in 2013 in patients with B-cell
hematologic cancers who have failed or relapsed on existing marketed
therapies or products in development, including patients with
identified mutations. Portola's fourth program, PRT2607 and other
highly selective Syk inhibitors, is partnered with Biogen Idec Inc. 
Mardi Dier
Portola Pharmaceuticals
Paul Laland
415 946 1071 
Press spacebar to pause and continue. Press esc to stop.